QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
QQQ   329.28 (+0.24%)
AAPL   174.15 (-0.23%)
MSFT   290.17 (-0.39%)
META   174.66 (-0.11%)
GOOGL   120.17 (+0.52%)
AMZN   142.30 (+0.14%)
TSLA   908.61 (-0.37%)
NVDA   187.73 (+2.39%)
NIO   19.91 (-0.85%)
BABA   90.74 (+1.08%)
AMD   100.44 (+2.21%)
T   18.43 (+0.05%)
MU   62.98 (+2.21%)
CGC   3.81 (-6.16%)
F   16.15 (+0.75%)
GE   79.21 (-0.89%)
DIS   122.67 (-0.11%)
AMC   19.29 (-9.69%)
PYPL   99.86 (+0.44%)
PFE   48.58 (-1.40%)
NFLX   245.17 (+1.67%)
NASDAQ:AXDX

Accelerate Diagnostics - AXDX Stock Forecast, Price & News

$2.49
-0.93 (-27.19%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.41
$2.96
50-Day Range
$0.64
$3.42
52-Week Range
$0.50
$7.19
Volume
2.37 million shs
Average Volume
712,439 shs
Market Capitalization
$173.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00

Accelerate Diagnostics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
59.8% Downside
$1.00 Price Target
Short Interest
Bearish
10.59% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.62
Upright™ Environmental Score
News Sentiment
0.70mentions of Accelerate Diagnostics in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$25,660 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.60 out of 5 stars

Medical Sector

1035th out of 1,119 stocks

Analytical Instruments Industry

27th out of 31 stocks

AXDX stock logo

About Accelerate Diagnostics (NASDAQ:AXDX) Stock

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Accelerate Diagnostics Stock Performance

AXDX Stock traded down $0.93 during mid-day trading on Thursday, reaching $2.49. The company had a trading volume of 2,371,153 shares, compared to its average volume of 712,439. The company has a market capitalization of $173.46 million, a price-to-earnings ratio of -2.68 and a beta of 1.51. The firm has a fifty day simple moving average of $1.43 and a 200 day simple moving average of $1.50. Accelerate Diagnostics has a fifty-two week low of $0.50 and a fifty-two week high of $7.19.

Accelerate Diagnostics (NASDAQ:AXDX - Get Rating) last issued its earnings results on Monday, August 15th. The medical research company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.05. During the same period last year, the business posted ($0.36) EPS.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Craig Hallum decreased their target price on Accelerate Diagnostics to $1.00 and set an "underperform" rating on the stock in a research note on Tuesday, May 17th. StockNews.com lowered Accelerate Diagnostics from a "hold" rating to a "sell" rating in a research report on Saturday, June 4th.

Insider Transactions at Accelerate Diagnostics

In related news, CEO Jack Phillips sold 28,198 shares of the firm's stock in a transaction that occurred on Wednesday, June 22nd. The stock was sold at an average price of $0.91, for a total transaction of $25,660.18. Following the transaction, the chief executive officer now owns 242,035 shares in the company, valued at approximately $220,251.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 42.20% of the company's stock.

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

Accelerate Diagnostics Reports Second Quarter 2022 Financial Results
Accelerate Diagnostics Q2 Net Loss Narrows
Here's what to expect from Accelerate Diagnostics's earnings
Accelerate Diagnostics Posts Smaller Q1 Loss
Accelerate Diagnostics Q1 2022 Earnings Preview
Earnings Preview For Accelerate Diagnostics
See More Headlines
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Company Calendar

Last Earnings
8/15/2022
Today
8/18/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Analytical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXDX
Employees
220
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.00
High Stock Price Forecast
$1.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
-59.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-77,700,000.00
Net Margins
-481.64%
Pretax Margin
-481.32%

Debt

Sales & Book Value

Annual Sales
$11.78 million
Book Value
($0.76) per share

Miscellaneous

Free Float
40,264,000
Market Cap
$173.46 million
Optionable
Optionable
Beta
1.51

Key Executives

  • Mr. Jack PhillipsMr. Jack Phillips (Age 56)
    CEO, Pres & Director
    Comp: $703.01k
  • Mr. Steve ReichlingMr. Steve Reichling (Age 44)
    Chief Financial Officer
    Comp: $340k
  • Mr. Ron PriceMr. Ron Price (Age 58)
    Chief Commercial Officer of Americas
    Comp: $240k
  • Laura Pierson
    Investor Relations Officer
  • Mr. Michael Bridge
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Gretchen Strohminger
    Sr. VP and Head of HR & Culture
  • Mr. Cherif Bousselham
    Sr. VP & Head of Sales - EMEA
  • Ms. Laura Costa
    Sr. VP & Head of Global Customer Support
  • Mr. John Meduri
    Chief Strategy Officer
  • Dr. Lawrence Mertz
    Sr. VP and Head of R&D













AXDX Stock - Frequently Asked Questions

Should I buy or sell Accelerate Diagnostics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" AXDX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXDX, but not buy additional shares or sell existing shares.
View AXDX analyst ratings
or view top-rated stocks.

What is Accelerate Diagnostics' stock price forecast for 2022?

2 brokerages have issued twelve-month target prices for Accelerate Diagnostics' shares. Their AXDX share price forecasts range from $1.00 to $1.00. On average, they expect the company's stock price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 59.8%.
View analysts price targets for AXDX
or view top-rated stocks among Wall Street analysts.

How have AXDX shares performed in 2022?

Accelerate Diagnostics' stock was trading at $5.22 at the start of the year. Since then, AXDX stock has decreased by 52.3% and is now trading at $2.49.
View the best growth stocks for 2022 here
.

When is Accelerate Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our AXDX earnings forecast
.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its earnings results on Monday, August, 15th. The medical research company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($0.28) by $0.05. During the same period in the previous year, the firm earned ($0.36) EPS.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional investors include Griffin Asset Management Inc. (5.72%), Citadel Advisors LLC (0.00%), JPMorgan Chase & Co. (0.54%), Belpointe Asset Management LLC (0.50%), Davidson Kempner Capital Management LP (0.36%) and State Street Corp (0.35%). Insiders that own company stock include Hany Massarany, Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends
.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $2.49.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics (NASDAQ:AXDX) has a market capitalization of $173.46 million and generates $11.78 million in revenue each year. The medical research company earns $-77,700,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

The company employs 220 workers across the globe.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The official website for the company is acceleratediagnostics.com. The medical research company can be reached via phone at (520) 365-3100, via email at investors@axdx.com, or via fax at 520-269-6580.

This page (NASDAQ:AXDX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.